Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Combination therapy does not meet primary endpoints in first-line PD-L1-high metastatic non-small cell lung cancer
5+ hour, 29+ min ago (26+ words) Medical Xpress This site can’t be reached medicalxpress.com refused to connect....
Iza-bren 2.5 mg/kg dose advances to Phase 3 in EGFR-mutated NSCLC
43+ min ago (362+ words) clinicaltrialvanguard.com Iza-bren 2.5 mg/kg dose advances to Phase 3 in EGFR-mutated NSCLC Three dose levels entered a randomized expansion cohort; only one came out with a Phase 3 ticket. SystImmune and Bristol Myers Squibb will present at WCLC in Seoul on…...
Kidney Stone Symptoms, Causes, and Effective Treatment Options
5+ hour, 7+ min ago (537+ words) Kidney stones are hard deposits made of minerals and salts that form within the kidneys when substances in urine become highly concentrated and crystallise. According to the American Journal of Kidney Diseases, these crystalline aggregates develop when the balance between…...
Akeso details survival win for its PD-1xVEGF drug versus Keytruda
5+ hour, 34+ min ago (76+ words) Endpoints News Akeso details survival win for its PD-1xVEGF drug versus Keytruda Akeso and Summit Therapeutics claimed a key win over Keytruda at the start of September,…...
Beyond the First-Line for ESR1-Mutated Disease
11+ hour, 9+ min ago (273+ words) An expert panel moderated by Sara Nunnery, MD, of Tennessee Oncology, convened to discuss how they choose therapy beyond the first-line setting for patients with ESR1-mutated disease. Dr. Nunnery was joined by Nan Chen, MD, of the University of Chicago;…...
Antibody-Drug Combination Falls Short in First-Line PD-L1-High Metastatic
11+ min ago (650+ words) A closely watched Phase 3 clinical trial has delivered a sobering verdict on one of the most anticipated treatment strategies in lung cancer medicine....
Shifting Identities: How Lung Cancer Cells Change Face to Outsmart
23+ min ago (69+ words) Small-cell lung cancer has long been one of oncology’s most punishing adversaries. It grows with astonishing speed, spreads early, and presents a treatment paradox that has frustrated clinicians for decades: at diagnosis, tumors melt away under platinum-based chemotherapy, yet relapse…...
Income Protects Breast Cancer Survivors From Heart Disease Unequally,
1+ hour, 14+ min ago (101+ words) Higher income has long been treated as a reliable shield against chronic disease, but a sweeping new analysis of female breast cancer survivors in the United States suggests that this protection is anything but uniform. Drawing on four years of…...
Therapeutic Vaccines for Ovarian Cancer Show Promise but Remain Stuck in
1+ hour, 27+ min ago (83+ words) Ovarian cancer remains one of the most lethal gynecologic malignancies, and for decades researchers have pursued an idea that sounds deceptively simple: train the patient’s own immune system to recognize and destroy tumor cells. A new analysis of the entire…...
Subcutaneous Tarlatamab Shows Safety and Early Activity in Small Cell Lung
2+ hour, 19+ min ago (651+ words) Patients with extensive-stage small cell lung cancer, one of the most difficult malignancies to treat once first-line therapy fails, may soon have a more convenient way to receive an immunotherapy that has already changed the treatment landscape....